ArticleEClinicalMedicine2025

Efficacy and safety of tislelizumab plus anlotinib and irinotecan as second-line treatment for extensive-stage small cell lung cancer: a single-arm, open-label, phase II trial.

Xian Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.